eV3 targets US PAD (peripheral artery disease) market:
This article was originally published in Clinica
Executive Summary
Eyeing a wider market opportunity for its Protege EverFlex self-expanding stent, ev3 is to begin a US clinical trial to test the device as a treatment for peripheral artery disease (PAD). The product is already available in the US for the palliative treatment of malignant neoplasms in the biliary tree. The US trial, called DURABILITY II, will be the first study in the treatment of PAD to explore use of a single stent in the treatment of lesions as long as 16cm and will include rigorous, five-year follow-up on stent fracture, claimed the Plymouth, Minnesota firm. According to the American Heart Association, PAD affects 8 million people in the US.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.